Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

GLAXOSMITHKLINE PLC Form 6-K May 02, 2012

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

#### FORM 6-K

**Report of Foreign Issuer** 

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

May 2, 2012

GlaxoSmithKline plc

GlaxoSmithKline Capital plc
(Name of registrant)

**GlaxoSmithKline Capital Inc.** 

(Name of registrant)

980 Great West Road,

1105 North Market Street,

## Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Brentford,

Suite 622, Wilmington,

Middlesex, TW8 9GS (Address of principal executive offices)

FURNISHED.

Delaware 19801 (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F x Form 40-F "
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes "No x
THIS REPORT ON FORM 6-K SHALL BE DEEMED TO BE INCORPORATED BY REFERENCE IN THE PROSPECTUS INCLUDED IN
THE REGISTRATION STATEMENT ON FORM F-3 (FILE NO. 333-172621) OF GLAXOSMITHKLINE PLC, GLAXOSMITHKLINE
CAPITAL INC. AND GLAXOSMITHKLINE CAPITAL PLC AND TO BE A PART THEREOF FROM THE DATE ON WHICH THIS
REPORT IS FURNISHED, TO THE EXTENT NOT SUPERSEDED BY DOCUMENTS OR REPORTS SUBSEQUENTLY FILED OR

## Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

GlaxoSmithKline plc, GlaxoSmithKline Capital plc and GlaxoSmithKline Capital Inc. hereby incorporate by reference the following exhibit to this report on Form 6-K into their Registration Statement on Form F-3 (File Nos. 333-172621, 333-172621-01, 333-172621-02).

Exhibit

No. Description of Document

12.1 Statement of Computation of Ratio of Earnings to Fixed Charges.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on their behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc

GlaxoSmithKline Capital plc and

GlaxoSmithKline Capital Inc.

(Registrants)

Date: May 2, 2012

By: /s/ VICTORIA WHYTE

Victoria Whyte

Authorised Signatory for and on behalf of

GlaxoSmithKline plc

GlaxoSmithKline Capital plc and

GlaxoSmithKline Capital Inc.